SCHEMBL6893494

SCHEMBL6893494

CC(=O)SCCN(CCC1CCCCC1)C(=O)NCC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 3/20 0.35
PHF8 Q9UPP1 3/20 0.35
KDM2A Q9Y2K7 3/20 0.35
KDM4C Q9H3R0 2/20 0.35
KDM4A O75164 1/20 0.35
CASR P41180 1/20 0.35
PPARG P37231 2/20 0.33
PPARA Q07869 2/20 0.33
GMNN O75496 1/20 0.33
USP2 O75604 1/20 0.33
USP1 O94782 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6898719 0.86 CASR (0.33) CASRPPARGPPARAGMNNUSP2
SCHEMBL6898124 0.85 CASR (0.32) CASREPHX1
SCHEMBL6734367 0.84 PKM (0.37) CASRPPARGPPARAGMNNUSP2
SCHEMBL6898252 0.82 HSD11B1 (0.36) ALDH1A1LMNATP53POLBMAPT
SCHEMBL6741613 0.82 SIGMAR1 (0.40) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL27541814 0.81 CASR (0.33) CASRPPARGPPARAGMNNUSP2
SCHEMBL27570949 0.81 CASR (0.33) CASRPPARGPPARAGMNNUSP2
SCHEMBL6896738 0.81 LTA4H (0.39) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL6894617 0.81 LTA4H (0.39) KDM5APHF8KDM2AKDM4CKDM4A
SCHEMBL6890761 0.81 LTA4H (0.39) KDM5APHF8KDM2AKDM4CKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH KDM5A 3320/4885PHF8 3425/4885KDM2A 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.